Scandion Oncology
1.395 SEK +7.72%Be the first to follow this company
Scandion Oncology is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has been used in certain standard cancer treatments during preclinical studies. The company was founded in 2017 and is headquartered in Copenhagen, Denmark.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
SCOL
Daily low / high price
1.295 / 1.4
SEK
Market cap
56.79M SEK
Turnover
10.37K SEK
Volume
7.4K
Latest videos
Financial calendar
Interim report
2024-05-29
Interim report
2024-08-29
Interim report
2024-11-27
Annual report
2025-02-28
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Saniona | 18.2 % | 18.2 % |
Jan Stenvang | 7.3 % | 7.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Scandion Oncology – Notice convening the Annual General Meeting
SCANDION ONCOLOGY CARRIES OUT A RIGHTS ISSUE OF APPROXIMATELY SEK 60 MILLION SECURED UP TO APPROXIMATELY SEK 30.6 MILLION
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools